RxDoctor Payments Data

Cesar Trabanco, MD

Endocrinology, Diabetes & Metabolism · Ponce, PRNPI 1104018654

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $17,310 of the $20,179 with a category attached, or 85.8%. Johnson & Johnson accounts for 65.7% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2019 at $15,861 and has fallen 98.8% since, to $193 in 2025.

$20,179in general payments, 2019–2025

Across 38 payments — averaging $531.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$13K
  • Merck$6K
  • Sanofi-aventis U.S. LLC$300
  • Abbott$184
  • Madrigal Pharmaceuticals$148
  • GSK$128
  • plus $323 from 5 others

What the payments were for

  • Consulting fees$1,3257%
  • Speaking & faculty fees$17,31086%
  • Food & beverage$1,5198%
  • Education$250%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$20,179 in reported general payments places this provider in the 85th percentile of 143 endocrinology, diabetes & metabolism providers in Puerto Rico.

See all endocrinology, diabetes & metabolism providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$35,401
Medicare patients
110
Services billed
339

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanumetSitagliptin Phos/Metformin Hcl659$448,881
SynjardyEmpagliflozin/Metformin Hcl519$331,849
SynthroidLevothyroxine Sodium5,287$328,023
OzempicSemaglutide206$203,206
JardianceEmpagliflozin268$196,190
FarxigaDapagliflozin Propanediol241$172,032
TradjentaLinagliptin241$146,836
JentaduetoLinagliptin/Metformin Hcl204$131,496
JanuviaSitagliptin Phosphate146$91,524
Janumet XrSitagliptin Phos/Metformin Hcl146$83,051
Tresiba Flextouch U-200Insulin Degludec90$54,894
Xigduo XrDapaglifloz Propaned/Metformin88$51,682
GlyxambiEmpagliflozin/Linagliptin75$47,885
LantusInsulin Glargine,hum.Rec.Anlog358$47,838
EliquisApixaban72$47,762

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanumet, Januvia, Janumet Xr$5,832$623,455951 claims
Johnson & JohnsonInvokana, Xarelto, Invokamet$13,263$74,446108 claims
Sanofi-aventis U.S. LLCLantus$300$47,838358 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 143 endocrinology, diabetes & metabolism providers in Puerto Rico.

Other endocrinology, diabetes & metabolism in Ponce

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →